A bypass mechanism of abiraterone‐resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A bypass mechanism of abiraterone‐resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling
Authors
Keywords
-
Journal
PROSTATE
Volume 79, Issue 9, Pages 937-948
Publisher
Wiley
Online
2019-04-24
DOI
10.1002/pros.23799
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer
- (2018) Nobuaki Matsubara et al. Clinical Genitourinary Cancer
- Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe
- (2018) Johann S. de Bono et al. EUROPEAN UROLOGY
- Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
- (2018) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of Response to Enzalutamide Consecutively After Abiraterone Acetate/Prednisone Failure in Patients With Metastatic Castration-resistant Prostate Cancer
- (2018) Hamid Emamekhoo et al. Clinical Genitourinary Cancer
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- (2017) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
- (2017) Nicholas D. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5
- (2015) Karim Fizazi et al. JOURNAL OF CLINICAL ONCOLOGY
- Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial
- (2015) Fred Saad et al. LANCET ONCOLOGY
- Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer
- (2015) Zhenfei Li et al. NATURE
- Plasma AR and abiraterone-resistant prostate cancer
- (2015) Alessandro Romanel et al. Science Translational Medicine
- Phase I/II Trial of Orteronel (TAK-700)—an Investigational 17,20-Lyase Inhibitor—in Patients with Metastatic Castration-Resistant Prostate Cancer
- (2014) Robert Dreicer et al. CLINICAL CANCER RESEARCH
- Canonical Androstenedione Reduction Is the Predominant Source of Signaling Androgens in Hormone-Refractory Prostate Cancer
- (2014) M. Fankhauser et al. CLINICAL CANCER RESEARCH
- Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors
- (2014) E. J. Chen et al. CLINICAL CANCER RESEARCH
- Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial
- (2014) Gerhardt Attard et al. EUROPEAN UROLOGY
- Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)
- (2014) Dana E. Rathkopf et al. EUROPEAN UROLOGY
- Intense Androgen-Deprivation Therapy With Abiraterone Acetate Plus Leuprolide Acetate in Patients With Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study
- (2014) Mary-Ellen Taplin et al. JOURNAL OF CLINICAL ONCOLOGY
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen dynamics and serum PSA in patients treated with abiraterone acetate
- (2014) C J Ryan et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Limited in vitro efficacy of CYP17A1 inhibition on human castration resistant prostate cancer
- (2014) Takeo Kosaka et al. STEROIDS
- Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer
- (2013) R.J. van Soest et al. EUROPEAN JOURNAL OF CANCER
- Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone
- (2013) Andres Jan Schrader et al. EUROPEAN UROLOGY
- Assessment of steroidogenesis and steroidogenic enzyme functions
- (2013) Van Luu-The JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Garcinia vilersiana bark extract activates the Nrf2/HO-1 signaling pathway in RAW264.7 cells
- (2013) Yasuhiro Shinkai et al. JOURNAL OF TOXICOLOGICAL SCIENCES
- Characterization of Prostate Cancer Bone Metastases According to Expression Levels of Steroidogenic Enzymes and Androgen Receptor Splice Variants
- (2013) Emma Jernberg et al. PLoS One
- Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100
- (2012) J. Richards et al. CANCER RESEARCH
- Abiraterone Inhibits 3 -Hydroxysteroid Dehydrogenase: A Rationale for Increasing Drug Exposure in Castration-Resistant Prostate Cancer
- (2012) R. Li et al. CLINICAL CANCER RESEARCH
- Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys
- (2012) Masuo Yamaoka et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors
- (2011) C. Cai et al. CANCER RESEARCH
- Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants
- (2011) Elahe A. Mostaghel et al. CLINICAL CANCER RESEARCH
- Direct Regulation of Androgen Receptor Activity by Potent CYP17 Inhibitors in Prostate Cancer Cells
- (2011) Harris S. Soifer et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer
- (2011) Gerhardt Attard et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evidence of Limited Contributions for Intratumoral Steroidogenesis in Prostate Cancer
- (2010) J. Hofland et al. CANCER RESEARCH
- Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy
- (2010) Charles J. Ryan et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Androgen Levels Increase by Intratumoral De novo Steroidogenesis during Progression of Castration-Resistant Prostate Cancer
- (2008) J. A. Locke et al. CANCER RESEARCH
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
- (2008) R. B. Montgomery et al. CANCER RESEARCH
- Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol
- (2008) Paulette R. Dillard et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started